Infectious Disease
Marrazzo reports promising PrEP data for cisgender women
March 05, 2024
4 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
”
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
DENVER — A new study provides reassurances that PrEP can reliably prevent HIV in cisgender women, even if they do not use it daily.
In this video from the Conference on Retroviruses and Opportunistic Infections, National Institute of Allergy and Infectious Diseases Director Jeanne Marrazzo, MD, MPH, describes the current landscape of PrEP use among cisgender women and what it should look like going forward.
The new study demonstrated that cisgender women who used PrEP at least four times per week did not experience any HIV infections.
“As we know, PrEP works if you take it, but when you’re talking about cisgender women, I’m not sure we felt quite so comfortable in saying that without emphasizing the need to use it daily,” said Marrazzo, who co-authored the study. “And for that reason, I think a lot of women did not feel empowered to use it.”
Reference:
Published by:
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
”
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio